Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32215| Title: | INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). | Austin Authors: | Lam, Lyn Ley;Pavlakis, Nick;Shitara, Kohei;Sjoquist, Katrin M;Martin, Andrew J;Yip, Sonia;Kang, Yoon-Koo;Bang, Yung-Jue;Chen, Li-Tzong;Moehler, Markus;Bekaii-Saab, Tanios;Alcindor, Thierry;O'Callaghan, Christopher J ;Tebbutt, Niall C ;Hague, Wendy;Chan, Howard;Rha, Sun Young;Lee, Keun-Wook;Gebski, Val;Jaworski, Anthony;Zalcberg, John;Price, Timothy;Simes, John;Goldstein, David | Affiliation: | NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Sydney, Australia. integrateii.study@sydney.edu.au. Royal North Shore Hospital, Sydney, Australia. National Cancer Centre Hospital East, Chiba, Japan. NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Sydney, Australia. Asan Medical Centre, Seoul, South Korea. Seoul National University College of Medicine, Seoul, South Korea. College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. University Medical Centre Mainz, Mainz, Germany. Mayo Clinic Comprehensive Cancer Centre, Phoenix, USA. McGill University Health Centre, Montreal, Canada. Olivia Newton-John Cancer Wellness and Research Centre NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Sydney, Australia. Calvary Mater Newcastle, Waratah, Australia. Yonsei Cancer Centre, Yonsei University Health System, Seoul, South Korea. Seoul National University College of Medicine, Seoul, South Korea. Monash University Melbourne, Melbourne, Australia. The Queen Elizabeth Hospital, Adelaide, Australia. Prince of Wales Hospital, Sydney, Australia. |
Issue Date: | 22-Feb-2023 | Date: | 2023 | Publication information: | BMC cancer 2023; 23(1) | Abstract: | Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targeting angiogenic, stromal, and oncogenic receptor tyrosine kinases. Regorafenib 160 mg daily prolonged progression free survival compared to placebo (INTEGRATE, phase 2). Regorafenib 80 mg daily in combination with nivolumab 3 mg/kg showed promising objective response rates (REGONIVO). | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32215 | DOI: | 10.1186/s12885-023-10642-7 | ORCID: | Journal: | BMC cancer | Start page: | 180 | PubMed URL: | 36814222 | ISSN: | 1471-2407 | Type: | Journal Article | Subjects: | Advanced gastro-oesophageal cancer Clinical trial Nivolumab Regorafenib Tyrosine kinase inhibitor Nivolumab/therapeutic use Pyridines/therapeutic use Stomach Neoplasms/drug therapy Esophageal Neoplasms/drug therapy |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.